Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT

Bone Marrow Transplantation

Volumn 43, Issue 9, 2009, Pages 669-677

  Kobbe, G ^a   Bruns, I ^a   Fenk, R ^a   Czibere, A ^a   Haas, R ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; PLACEBO; PLATINUM COMPLEX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE PAIN; CELL FUNCTION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; LYMPHOMA; MULTIPLE MYELOMA; MYALGIA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; STEM CELL MOBILIZATION;

FILGRASTIM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KINETICS; TRANSPLANTATION, AUTOLOGOUS;

EID: 67349288092     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.59     Document Type: Review

References (58)

1. Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978; 52: 85-95.
2. Abrams RA, Deisseroth AB. Prospects for accelerating hematopoietic recovery following myelosuppressive therapy by using autologous, cryopreserved hematopoietic stem cells collected solely from the peripheral blood. Exp Hematol 1979; 7 (Suppl 5): 107-115.
3. Haas R, Ho AD, Bredthauer U, Cayeux S, Egerer G, Knauf W et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990; 18: 94-98.
4. Neben S, Marcus K, Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993; 81: 1960-1967.
5. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
6. Haas R, Witt B, Mohle R, Goldschmidt H, Hohaus S, Fruehauf S et al Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754-3761.
7. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
8. Tabbara IA, Ghazal CD, Ghazal HH. The clinical applications of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation: A review. Anticancer Res 1996; 16: 3901-3905.
9. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB. Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006; 46: 747-757.
10. Martin-Murea S, Voso MT, Hohaus S, Pforsich M, Fruehauf S, Goldschmidt H et al. The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol 1998; 101: 582-585.
11. Kobbe G, Sohngen D, Bauser U, Schneider P, Germing U, Thiele KP et al Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol 1999; 78 456-462.
12. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M et al Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
13. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
14. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
15. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-519.
16. Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W, Blay JY et al. Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. J Clin Oncol 2002; 20: 24-36.
17. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L et al. randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
18. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-36.
19. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al. A single dose of 6 or 12mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180-185.
20. Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405-412.
21. Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006; 34: 1296-1302.
22. Haas R, Gericke G, Witt B, Cayeux S, Hunstein W. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol 1993; 21: 109-113.
23. Tricot G, Barlogie B, Zangari M, van RF, Hoering A, Szymonifka J et al. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica 2008; 93: 1739-1742.
24. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-231.
25. Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Barate C et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatinaracytin-containing regimens. Bone Marrow Transplant 2006; 38: 413-416.
26. Kroschinsky F, Holig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46: 1417-1423.
27. Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J et al Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 743-750.
28. Haas R, Ehrhardt R, Witt B, Goldschmidt H, Hohaus S, Pforsich M et al Autografting with peripheral blood stem cells mobilized by sequential interieukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma. Bone Marrow Transplant. 1993; 12: 643-649.
29. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999; 23(Suppl 2): S29-S33.
30. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1253-1261.
31. Fricker SP. A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs 2008; 17: 1749-1760.
32. Jacoub JF, Suryadevara U, Pereyra V, Colon D, Fontelonga A, Mackintosh FR et al. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 2006; 34: 1443-1450.
33. Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I et al A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-765.
34. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
35. Kroschinsky F, Holig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34 + peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90: 1665-1671.
36. Hosing C, Qazilbash MH, Kebriaci P, Giralt S, Davis MS, Popat U et al Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 2006; 133: 533-537.
37. Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S et al Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008; 93: 347-355.
38. Sarkar CA, Lowenhaupt K, Wang PJ, Horan T, Lauffenburger DA. Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues. Biotechnol Prog 2003; 19: 955-964.
39. Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: A rational approach to separate GVHD and GVL? Blood 2006; 107: 3430-3435.
40. van AM, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: A prospective randomised trial. Eur J Cancer 2001; 37: 1781-1789.
41. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-457.
42. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207-5215.
43. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
44. Farese AM, MacVittie TJ, Roskos L, Stead RB. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF. Stem Cells 2003; 21: 79-89.
45. Straka C, Oduncu F, Hinke A, Einsele H, Drexler E, Schnabel B et al Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients. Blood 2004; 104 1989-1994.
46. Kuendgen A, Fenk R, Bruns I, Dommach M, Schutte A, Engers R et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 69-70.
47. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica 2006; 91: ECR08.
48. Piccirillo N, De MS, De VS, Laurenti L, Chiusolo P, Sora F et al. Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2007; 40: 579-583.
49. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 889-893.
50. Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: Phase II study. Bone Marrow Transplant 2005; 35: 1165-1169.
51. Martino M, Pratico G, Messina G, Irrera G, Massara E, Messina G et al Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006; 77: 410-415.
52. Vanstraelen G, Frere P, Ngirabacu MC, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006; 34: 382-388.
53. Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V et al Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008; 87: 49-55.
54. Gerds A, Fox-Geiman M, Dawravoo K, Rodriguez T, Toor A, Smith S et al A Phase III, randomized, placebo-controlled comparative trial of pegfilgrastim versus filgrastim after autologous stem cell transplantation(PBPSCT). Blood 2007; 110: 479.
55. Rader M. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: Clinical and economic benefits. Oncology (Williston Park) 2006; 20: 16-21.
56. Numnum TM, Kimball KJ, Rocconi RP, Kilgore LC, Straughn Jr JM. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma - a cost-effectiveness analysis. Int J Gynecol Cancer 2007; 17: 1019-1024.
57. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008; 11: 172-179.
58. Ng R, Green MD. Pegfilgrastim: Evidence in support of its use with cytotoxic chemotherapy. Expert Rev Anticancer Ther 2005; 5: 585-590.